Clinical trials
Phase 1 Hematologic Neoplasms trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 5 |
| iCell Gene Therapeutics | 4 |
| Acrotech Biopharma Inc. | 1 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | 1 |
| Biocity Biopharmaceutics Co., Ltd. | 1 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Huazhong University of Science and Technology | 1 |
| Hutchison Medipharma Limited | 1 |
| Institut Paoli-Calmettes | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Neoplasms | 23 |
| Leukemia | 5 |
| Leukemia, Myeloid, Acute | 3 |
| Neoplasms | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Myelodysplastic Syndromes | 2 |
| Myeloproliferative Disorders | 2 |
| Recurrence | 2 |
| Fibrosis | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.